# Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response

Study · id `cardio:ct-nct03715556` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03715556](<https://clinicaltrials.gov/study/NCT03715556>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03715556

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 126 participants.

## Technical summary

Registry record NCT03715556. Randomized; double masking; primary purpose treatment. Start 2018-12-01 (anticipated); primary completion 2020-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 126 participants (planned count; ClinicalTrials.gov record NCT03715556, source copy `cardio:ctgov-nct03715556-2018-10-23`, retrieved 2026-10-26)
- Planned start: 2018-12-01 (anticipated) (ClinicalTrials.gov record NCT03715556, source copy `cardio:ctgov-nct03715556-2018-10-23`, retrieved 2026-10-26)
- Primary completion: 2020-12-01 (anticipated) (ClinicalTrials.gov record NCT03715556, source copy `cardio:ctgov-nct03715556-2018-10-23`, retrieved 2026-10-26)
- Completion: 2021-12-01 (anticipated) (ClinicalTrials.gov record NCT03715556, source copy `cardio:ctgov-nct03715556-2018-10-23`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT03715556, source copy `cardio:ctgov-nct03715556-2018-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03715556-2018-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response
- Acronym: FAARV
- Condition: Sepsis
- Condition: Septic Shock
- Condition: Atrial Fibrillation
- Condition: Ventricular Fibrillation
- Condition: Atrial Fibrillation Rapid
- Intervention (Drug): Amiodarone
- Intervention (Drug): 0.9% physiological solution
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Amiodarone (`cardio:amiodarone`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)

## Provenance

Content hash: 9e7c3f97994dcd80de52bc7027f415c3aa90ed748696d849c5ae1eb04c21ae59
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
